Addressing Synaptic Deficits in Fragile X Syndrome and how SPG601 could help
BLOG Addressing Synaptic Deficits in Fragile X Syndrome and how SPG601 could help July is Fragile X Awareness Month. We take this timely opportunity to hear our Chief Medical Advisor and Director of the Cincinnati Fragile X Research and Treatment Center, Dr. Craig Erickson, describe how SPG601- our novel approach to addressing synaptic deficits in […]
Synapse loss in Alzheimer’s disease and how SPG302 can help
BLOG Synapse loss in Alzheimer’s disease and how SPG302 can help June is Alzheimer’s and Brain Awareness Month. We take this timely opportunity to hear our Chief Science Officer, Dr. Peter Vanderklish, describe how SPG302 – our novel, regenerative medicine approach to neurodegenerative diseases – can be of benefit in Alzheimer’s disease. The burden of […]
Courage and Connections: Dan Doctoroff and Stella Sarraf Discuss ALS, Synapses, and Spinogenix’s Innovative Approach
BLOG June 12, 2024 Courage and Connections: Dan Doctoroff and Stella Sarraf Discuss ALS, Synapses, and Spinogenix’s Innovative Approach By: Stella Sarraf, Ph.D., CEO and founder of Spinogenix Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, was first described over 150 years ago. Despite decades of research, it remains an incurable disease with […]
Using EEG and TMS to capture treatment-related Brain Signals in Spinogenix Drug Trials
BLOG Using EEG and TMS to capture treatment-related Brain Signals in Spinogenix Drug Trials Spinogenix is leveraging old and new neurophysiological readouts to maximize signal detection in their human drug trials. This has positive implications for conducting rapid, highly quantitative early phase trials that can significantly aid future development. Drug development is a complicated, expensive, […]
